PRESS RELEASE

Fredrik Lindberg is this year's Ideon prize winner

LUND, Sweden, January 2, 2012 - President and cofounder Fredrik Lindberg is awarded the Ideon prize for his journey with BONESUPPORT™ from an incubator enterprise to an international medical technology corporation.

Ideon Science Park announced today that this year's Ideon prize is awarded to Fredrik Lindberg, president and cofounder of BONESUPPORT™.

BONESUPPORT™ works with a ceramic, injectable bone substitute for treatment of osteoporosis fractures, among others. The corporation's basic product was developed from research at the Orthopedic Clinic at Lund University under the direction of Prof. Lars Lidgren.

Today, 10 years after the founding of BONESUPPORT™ ats Ideon's first incubator enterprise, the corporation has subsidiaries in the USA, the Netherlands and Germany with more than 30 employees.

'To be able to receive the Ideon prize from such an illustrious group as the members of the Ideon Society is recognition far beyond the usual. As an entrepreneur, one always places his company and its employees in the front row, but once in a while it can be a pleasure to be singled out personally. I am both happy and proud and now have more fuel for my passion to turn BONESUPPORT™ into an internationally successful corporation', says Fredrik Lindberg.

The citation reads as follows:
'This year's Ideon prizewinner has spent a good 10 years starting and building a very promising company that is now going into a commercial phase and has great possibilities for finding the world at its feet.

The prizewinner has a highly developed ability to combine both leadership and salesmanship and has the heart and soul of a research scientist as well. The company that he has built out of the original laboratory report has produced products that already have helped and are going to help many people to a significantly better life.'

With strong financing, BONESUPPORT™ has been able to attract significant risk capital totaling 490 million kronor and this year alone Industrifonden, HealthCap and Lundbeckfond Ventures invested 170 million kronor in the company. The potential market for bone substitute in Europe alone is around 3 billion kronor and many times that for the US market.